Rolimus 5mg

Rolimus 5mg containing an active ingredient known as Everolimus which is intercedes with cancer cell growth and slows down its process. Rolimus 5mg tablets are not used as curable medicine, which is used to slow their spreading in to the body.

Everolimus

Rolimus

5mg

Cipla




Rolimus 5MG PRESCRIBING INFORMATION

Rolimus 5mg tablets are mainly indicated in:

Renal carcinoma Breast carcinoma Brain carcinoma Everolimus is also used in various advanced stage cancer in stomach, intestines or pancreas.

Rolimus 5MG MECHANISM

Everolimus is an mTOR prohibitor, binds at high compatibility to FK506 binding protein 12, through producing drug complex that prohibits the effective of mTOR.

This prohibition decrease the activity of effectors downstream, which may causes blockage of cell progression from G1 into S phase, subsequently causes cell growth arrest and apoptosis



Pharmacokinetic

The peak plasma concentration time of Everolimus reaches within 1 to 2 hours. The effect of food with Rolimus 5mg is given below; With heavy meal: Reduction of systemic exposure to Rolimus 5mg 10mg, and the peak blood plasma concentration by 54%.

The blood plasma ratio of Rolimus 5mg with the range of 5 to 5000mg/ml is 17% to 73%.Rolimus 5mg human plasma protein bound with the range of 74%.

The metabolism of Everolimus is occurred in liver, which is a substrate of CYP3A4. The metabolites of Everolimus; Three monohydroxylated metabolite, Two hydrolytic rings opened products, & Phosphatidylcholine conjugate of Everolimus.

The terminal half-life period of Everolimus is relatively 30 hours The major route of elimination; 5% in urine; the parent compound has been detected in urine or feces.




Blueberrypharma.com-img1

Rolimus 5mg
Brand Rolimus
Ingredients Everolimus
Strength 5mg
Manufactured Cipla
Rating

DOSAGE REGIMEN AND ADMINISTRATION OF Rolimus

In breast cancer, renal cell cancer, pancreatic cancer, Neuro endocrine cancer: The recommended dosage is 10mg should be taken as a single dose.

In Brain or intracranial cancer:
The recommended dosage of Rolimus is 4.5mg/m2 orally as a single dose.

In pediatric:
The usual pediatric dosage of Rolimus in brain or intracranial tumor is 4.5mg/m2 should be taken orally as a single dose. Rolimus tablets should be administered with or without food.

Rolimus 5MG CAUSED SIDE EFFECTS

Hypersensitivity reactions, Lymphomas & other malignancy, Serious infections, Kidney graft thrombosis, Hepatic artery thrombosis, Nephrotoxicity, Hyperlipemia, Angioedema, Interstitial lung disease, Thrombocytopenia, Male infertility, Proteinuria, New commencement of diabetes

SAFETY MEASURES

Lymphomas:
Increased exposure of skin cancers, patient may protect from UV light

Serious infections:
Patients receiving Rolimus 5mg have high risk of acquiring various infections related to bacteria, virus, and fungi. Anti-microbial agents are preferred for the suspected patients.

Hepatic artery thrombosis:
In liver transplant patients, Rolimus 5mg therapy should not be recommended.

Nephrotoxicity:
Renal function should be monitored frequently; caution should be taken while using Rolimus 5mg in renal impaired patients.

Angioedema:
This may have occurred in the patients receiving concomitantly Rolimus 5mg with Angiotensin converting enzyme agents

Hyperlipidaemia:
Patient getting Rolimus 5mg with lipid lowering drugs causes increasing in plasma concentration of these drugs causes hyperlipidaemia

Interstitial lung disease:
Occurred in Rolimus 5mg therapy

Thrombocytopenia:
Using Rolimus 5mg with cyclosporine causes thrombocytopenia

Outbreak of diabetes:
Blood glucose level should be monitored

Embryo fetal toxicity:
Causes fetal damage using Rolimus 5mg in pregnancy condition

Immunization:
Using live vaccines in Rolimus 5mg therapy

Hereditary disorders:
In the conditions like galactose intolerance, glucose-galactose malabsorption, Rolimus 5mg should not be used may results in diarrhea & malabsorption.

Interact with grape juice:
Causes increasing blood levels of Everolimus; avoid these concomitants.

DRUG – DRUG INTERACTION

  • Rolimus 5mg is metabolized hepatically, a substrate of CYP3A4.
  • Rolimus 5mg combined with strong inhibitor of CYP3A4, or P-gp, leads to cause decreasing the efflux of Everolimus and increase the plasma concentration of Everolimus.
  • Rolimus 5mg with strong CYP3A4 inducers, causes increasing the exposure of Everolimus.
  • Co administration of Rolimus 5mg with cyclosporine causes increasing the AUC level of Everolimus frequently.
  • Rolimus 5mg tablet is combined with ketaconazole or other CYP3A4 inhibitors causes increasing the plasma concentration and AUC of Everolimus.
  • Concomitant of Rolimus 5mg with erythromycin causes increasing in AUC of Everolimus.
  • Co administration of Rolimus 5mg with verapamil leads to increasing the plasma concentration of Everolimus.
  • Co administration of Rolimus 5mg with Atorvastatin or pravastatin causes rhabdomyolysis, due to increasing concentration of lipid lowering agents.

Contraindications


Some anaphylactic reaction occurs, if patients are contraindicated to the components present in the Rolimus 5mg tablets.



Pregnancy category of Everolimus C Rolimus 5mg is used only by the patients after knowing the benefits to the mother outweighs the risk to fetus. Breast feeding should not be suggested

Rolimus 5mg tablet should be kept at 25°C Keep the tablet away from moisture, heat and light

In case of missed dose, patients must consult with medical practitioner and follow the instructions given by them. On the other hand, the missed dose should be avoiding and follow the regular dosing schedule.

The over dosage of Everolimus is rarely occur, in case of over dosage patient must be provide with supportive measures. The acute toxicity of Everolimus over dosage should be monitored.

Blueberrypharma.com-img2



Quick Contact




Prescription upload






PRESCRIPTION


Blueberrypharma.com , a fully licensed and regulated pharmacy medicine, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.

Blueberrypharma.com will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.

The drug information provided in the Blueberrypharma.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.

Blueberrypharma.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Blueberrypharma.com

At Blueberrypharma.com , a Caregiver can order prescription medicines on your behalf.